A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 500
- Registration Number
- NCT05841030
- Locations
- 🇺🇸
University of Alabama at Birmingham, Homewood, Alabama, United States
🇺🇸ATP Clinical Research, California City, California, United States
🇺🇸University of Connecticut Health Center, Farmington, Connecticut, United States
A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT05827874
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05818683
- Locations
- 🇺🇸
Washington University School Of Medicine, Saint Louis, Missouri, United States
🇺🇸Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
- Conditions
- Interventions
- First Posted Date
- 2023-04-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 305
- Registration Number
- NCT05811351
- Locations
- 🇵🇹
Uls Coimbra - Hosp. Univ. Coimbra, Coimbra, Portugal
🇨🇭Inselspital Universitatsspital Bern, Bern, Switzerland
🇺🇸Retinal Research Institute, Phoenix, Arizona, United States
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
- Conditions
- Interventions
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT05784441
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Iowa Hospital, Iowa City, Iowa, United States
🇦🇺Monash Medical Centre, Clayton, Australia
A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 4
- Registration Number
- NCT05784129
- Locations
- 🇺🇸
Gastro Health Ohio, Cincinnati, Ohio, United States
🇺🇸Southern Star Research Institute, LLC, San Antonio, Texas, United States
🇺🇸Medical Associates Research Group, Inc., San Diego, California, United States
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05757973
- Locations
- 🇬🇧
DUMMY, Dummy, United Kingdom
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20000
- Registration Number
- NCT05757869
- Locations
- 🇺🇸
The Queens Medical Center, Honolulu, Hawaii, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸Advocate Heart Institute, Oak Lawn, Illinois, United States
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16000
- Registration Number
- NCT05754957
- Locations
- 🇺🇸
Northwest Heart Clinical Research, LLC., Tomball, Texas, United States
🇮🇳Lisie Hospital, Cochin, India
🇮🇳Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, India
A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 64
- Registration Number
- NCT05742594
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States